Modafinil and γ-hydroxybutyrate have sleep state-specific pharmacological actions on hypocretin-1 physiology in a primate model of human sleep

Behavioural Pharmacology

Volumn 20, Issue 7, 2009, Pages 643-652

  Zeitzer, Jamie M ^a,b,d   Buckmaster, Christine L ^a   Landolt, Hans Peter ^c   Lyons, David M ^a   Mignot, Emmanuel ^a  

^a STANFORD UNIVERSITY   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d 3801 Miranda Avenue ^*  (United States)

Author keywords

Gamma hydroxybutyrate; Hypocretin; Modafinil; Orexin; Pharmacology; Sleep

Indexed keywords

4 HYDROXYBUTYRIC ACID; MODAFINIL; OREXIN A; PLACEBO;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RESPONSE; MALE; NONHUMAN; RHESUS MONKEY; SLEEP INDUCTION; SLEEP WAKING CYCLE;

ANIMALS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; HYDROCORTISONE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MODELS, ANIMAL; NEUROPEPTIDES; SAIMIRI; SLEEP; SODIUM OXYBATE; WAKEFULNESS;

EID: 70349654130     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328331b9db     Document Type: Article

References (41)

1. Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L (2007). Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 450:420-424.
2. Beardsley PM, Balster RL, Harris LS (1996). Evaluation of the discriminative stimulus and reinforcing effects of gammahydroxybutyrate (GHB). Psychopharmacol 127:315-322.
3. Bé racochéa D, Liscia P, Tronche C, Chauveau F, Jouanin J-C, Piérard C (2008). Stress modulation of the memory retrograde-enhancing effects of the awakening drug modafinil in mice. Psychopharmacol 196:1-13.
4. Berridge CW, España RA (2005). Hypocretins: waking, arousal, or action? Neuron 46:696-698.
5. Brun J, Chamba G, Khalfallah Y, Girard P, Boissy I, Bastuji H, et al. (1998). Effect of modafinil on plasma melatonin, cortisol and growth hormone rhythms, rectal temperature and performance in healthy subjects during a 36 h sleep deprivation. J Sleep Res 7:105-114.
6. Carai MA, Lobina C, Maccioni P, Cabras C, Colombo G, Gessa GL (2008). Gamma-aminobutyric acidB (GABAB)-receptor mediation of different in vivo effects of gamma-butyrolactone. J Pharmacol Sci 106:199-207.
7. Castelli MP, Mocci I, Langlois X, GommerenW, LuytenWHML, Leysen JE, Gessa GL (2000). Quantitative autoradiographic distribution of g-hydroxybutyric acid binding sites in human and monkey brain. Mol Brain Res 78:91-99.
8. Chemelli RM,Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437-451.
9. Crunelli V, Emri Z, Leresche N (2006). Unravelling the brain targets of g-hydroxybutyric acid. Curr Opinon Pharmacol 6:44-52.
10. Deboer T, Overeem S, Visser NAH, Duindam H, Frölich M, Lammers GJ, Meijer JH (2004). Convergence of circadian and sleep regulatory mechanisms on hypocretin-1. Neurosci 129:727-732.
11. Doherty JD, Hattox SE, Snead OC, Roth RH (1978). Identification of endogenous g-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig and rhesus monkey brain. J Pharmacol Exp Ther 207:130-139.
12. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, et al. (1999). Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 96:10911-10916.
13. Hermant J-F, Rambert FA, Duteil J (1991). Awakening properties of modafinil: effect on nocturnal activity in monkeys (Macaca mulatta) after acute and repeated administration. Psychopharmacol 103:28-32.
14. Ivanenko A, Tauman R, Gozal D (2003). Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 4:579-582.
15. Lagarde D, Milhaud C (1990). Electroencephalographic effects of modafinil, an alpha-1-adrenergic psychostimulant, on the sleep of rhesus monkeys. Sleep 13:441-448.
16. Lee MG, Hassani OK, Jones BE (2005). Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 25:6716-6720.
17. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. (2002). The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59:1553-1562.
18. Mileykovskiy BY, Kiyashchenko LI, Siegel JM (2005). Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 46:787-798.
19. Mosteller RD (1987). Simplified calculation of body-surface area. N Engl J Med 317:1098.
20. Nakamura RK, Myslobodsky MS, Coppola R, Johannesen-Conway J, Mirsky AF (1987). Effects of g-hydroxybutyrate on the performance of monkeys in a Go/No-go visual discrimination task. Beh Brain Res 26:19-27.
21. Piérard C, Liscia P, Valleau M, Drouet I, Chauveau F, Huart B, et al. (2006). Modafinil-induced modulation of working memory and plasma corticosterone in chronically-stressed mice. Pharmacol Biochem Behavior 83:1-8.
22. Qu WM, Huang ZL, Xu XH, Matsumoto N, Urade Y (2008). Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci 28:8462-8469.
23. Rao Y, Liu Z-W, Borok E, Rabenstein RL, Shanabrough M, Lu M, et al. (2007). Prolonged wakefulness induces experience-dependent synaptic plasticity in mouse hypocretin/orexin neurons. J Clin Invest 117:4022-4033.
24. Salomon RM, Ripley B, Kennedy JS, Johnson B, Zeitzer JM, Nishino S, Mignot E (2003). Diurnal variation of CSF hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol Psychiatry 54:96-104.
25. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS, Saper CB (2000). Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 20:8620-8628.
26. Shelton J, Nishino S, Vaught J, Dement WC, Mignot E (1995). Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 18:817-826.
27. Snead OC III (1978). Gamma hydroxybutyrate in the monkey. I. Electroencephalographic, behavioral, and pharmacokinetic studies. Neurol 28:636-642.
28. Tononi G, Cirelli C (2007). Staying awake puts pressure on brain arousal systems. J Clin Invest 117:3648-3650.
29. van Vliet SA, Jongsma MJ, Vanwersch RA, Olivier B, Philippens IH (2008). Efficacy of caffeine and modafinil in counteracting sleep deprivation in the marmoset monkey. Psychopharmacol (Berl) 197:59-66.
30. Willie JT, Renthal W, Chemelli RM, Miller MS, Scammell TE, Yanagisawa M, Sinton CM (2005). Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neurosci 130:983-995.
31. Wisor JP, Eriksson KS (2005). Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neurosci 132:1027-1034.
32. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM (2001). Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21:1787-1794.
33. Woolverton WL, Rowlett JK, Winger G, Woods JH, Gerak LR, France CP (1999). Evaluation of the reinforcing and discriminative stimulus effects of g-hydroxybutyrate in rhesus monkeys. Drug Alcohol Depend 54:137-143. (Pubitemid 29114992)
34. Wu M-F, John J, Maidment N, Lam HA, Siegel JM (2002). Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am J Physiol 283:R1079-R1086.
35. Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H, Yoneda H, et al. (2001). Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 14:1075-1081.
36. Yoshimichi G, Yoshimatsu H, Masaki T, Sakata T (2001). Orexin-A regulates body 40-temperature in coordination with arousal status. Exp Biol Med 226:468-476.
37. Zeitzer JM, Mignot E (2006). Role of hypocretin/orexin in the neurobiology of sleep and alertness. In: Bassetti C, Billiard M, Mignot E, editors. Narcolepsy and hypersomnia. New York: Informa Healthcare. pp. 359-374.
38. Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, Mignot E (2003). Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 23:3555-3560.
39. Zeitzer JM, Buckmaster CL, Lyons DM, Mignot E (2004). Locomotor-dependent and independent components to hypocretin-1 (orexin A) regulation in sleepwake consolidating monkeys. J Physiol 557:1045-1053.
40. Zeitzer JM, Buckmaster CL, Lyons DM, Mignot E (2007). Effects of increasing length of wakefulness on hypocretin-1 in the wake-consolidating squirrel monkey. Am J Physiol 293:R1736-R1742.
41. Zhang S, Zeitzer JM, Yoshida Y,Wisor JP, Nishino S, Edgar DM, Mignot E (2004). Lesions of the suprachiasmatic nucleus eliminate the daily rhythm of hypocretin-1 release. Sleep 27:619-627.